Press Releases - News & Events - Frequency Therapeutics

News & Events

Press Releases & News

Press Releases


2019 | 2018 | 2017

Frequency Therapeutics Completes Enrollment in Single Dose Safety Trial to Evaluate FX-322, a First-in-Class Drug Candidate for Hearing Restoration
- October 4, 2018

Frequency Therapeutics Strengthens Scientific Advisory Board with Addition of Leading Experts in Neurology, Stem Cell and Regenerative Medicine
- August 14, 2018

Frequency Therapeutics Initiates Phase 1/2 Single Dose Clinical Trial to Evaluate FX-322, a First-in-Class Drug Candidate for Hearing Restoration
- August 7, 2018

Frequency Therapeutics’ Co-founder and VP, Will McLean, Ph.D., Named To MIT Technology Review’s 2018 Innovators Under 35 List   
- June 27, 2018

U.S. Department of Defense Awards $2M Grant to Frequency Therapeutics  
- May 30, 2018

Frequency Therapeutics to Lead Featured Session at the American Academy of Audiology Annual Conference
- April 18, 2018

Frequency Therapeutics Continues Expansion of Leadership Team with Appointment of Dr. William Chin as Chief Medical Officer
- April 13, 2018

Science Magazine Recognizes Frequency Therapeutics’ PCA Regeneration Technology as a Breakthrough in Regenerative Medicine 
- March 20, 2018

Frequency Therapeutics Welcomes Former Otonomy CSO as Executive Vice President of Clinical Development
- March 12, 2018

Frequency Therapeutics to Present Corporate Update at Cowen & Company 38th Annual Health Care Conference
- March 6, 2018

Frequency Therapeutics Awarded Grant from JDRF to Generate Glucose-Responsive Insulin-Secreting Cells for Type 1 Diabetes Treatment Using a Small Molecule Approach  
- February 22, 2018

Three-way Collaboration with the U.S. Army, Harvard University and Frequency Therapeutics to Focus on Progenitor Cell Regeneration in Muscle
- February 15, 2018

Media Inquiries
Michael Lampe or 
Beth Kramli
Scient Public Relations
Tel: 484-575-5040
Email: FrequencyTx@scientpr.com